An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder

Psychiatric Genetics

Volumn 16, Issue 4, 2006, Pages 133-138

  Suzuki, Atsuko ^a   Nakamura, Kazuhiko ^a   Sekine, Yoshimoto ^a,b   Minabe, Yoshio ^a   Takei, Nori ^a   Suzuki, Katsuaki ^a   Iwata, Yasuhide ^a   Kawai, Masayoshi ^a   Takebayashi, Kiyokazu ^a   Matsuzaki, Hideo ^a   Iyo, Masaomi ^b   Ozaki, Norio ^b,c   Inada, Toshiya ^b,d   Iwata, Nakao ^e   Harano, Mutsuo ^b,f   Komiyama, Tokutaro ^b,g   Yamada, Mitsuhiko ^b,g   Sora, Ichiro ^b,h   Ujike, Hiroshi ^b,i   Mori, Norio ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL INSTITUTE OF MENTAL HEALTH   (Japan)

^h TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ OKAYAMA UNIVERSITY   (Japan)

Author keywords

Association study; Catechol O methyl transferase; Met allele; Methamphetamine psychosis; Spontaneous relapse

Indexed keywords

CATECHOL METHYLTRANSFERASE; METHAMPHETAMINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RELAPSE; RISK ASSESSMENT; COMPARATIVE STUDY; GENETICS; GENOTYPE; MIDDLE AGED; RECURRENT DISEASE; REFERENCE VALUE;

ADULT; AGED; CATECHOL O-METHYLTRANSFERASE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; METHAMPHETAMINE; MIDDLE AGED; POLYMORPHISM, GENETIC; PSYCHOTIC DISORDERS; RECURRENCE; REFERENCE VALUES;

EID: 33748436265     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ypg.0000218613.35139.cd     Document Type: Article

References (39)

1. Alsobrook JP 2nd, Zohar AH, Leboyer M, Chabane N, Ebstein RP, Pauls DL (2002). Association between the COMT locus and obsessive-compulsive disorder in females but not males. Am J Med Genet 114:116-120.
2. Buffenstein A, Heaster J, Ko P (1999). Chronic psychotic illness from methamphetamine [Letter]. Am J Psychiatry 156:662.
3. Davidson C, Gow AJ, Lee TH, Ellinwood EH (2001). Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Rev 36:1-22.
4. Fujiwara Y, Kazahaya Y, Nakashima M, Sato M, Otsuki S (1987). Behavioral sensitization to methamphetamine in the rat: an ontogenic study. Psychopharmacology (Berlin) 91:316-319.
5. Gogos JA, Morgan M, Luine V, Santha M, Ogawa S, Pfaff D, et al. (1998). Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci U S A 95:9991-9996.
6. Goldstein RZ, Volkow ND (2002). Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex. Am J Psychiatry 159:1642-1652.
7. Horowitz R, Kotler M, Shufman E, Aharoni S, Kremer I, Cohen H, et al. (2000). Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. Am J Med Genet 96:599-603.
8. Huotari M, Garcia-Horsman JA, Karayiorgou M, Gogos JA, Mannisto PT (2004). D-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology (Berlin) 172:1-10.
9. Iwanami A, Sugiyama A, Kuroki N, Toda S, Kato N, Nakatani Y, et al. (1994). Patients with methamphetamine psychosis admitted to a psychiatric hospital in Japan: a preliminary report. Acta Psychiatr Scand 89:428-432.
10. Iwanami A, Kuwakado D, Otsubo T, Ishono H, Kamijima K (1997). Relapse of panic disorder induced by a single intravenous methamphetamine injection. J Anxiety Disord 11:113-116.
11. Iyo M, Sekine Y, Matsunaga T, Tsukamoto T, Takei N, Mori N (1999). Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report. J Clin Psychiatry 60:337-338.
12. Kalivas PW, Stewart J (1991). Dopamine transmission in the initiation and expression of drug- and stress-induced sensitization of motor activity. Brain Res Rev 16:223-244.
13. Karayiorgou M, Altemus M, Galke BL, Goldman D, Murphy DL, Ott J, et al. (1997). Genotype determining low catechol-O-methyltransferase activity as a risk factor for obsessive-compulsive disorder. Proc Natl Acad Sci U S A 94:4572-4575.
14. Kelley AE, Berridge KC (2002). The neuroscience of natural rewards: relevance to addictive drugs. J Neurosci 22:3306-3311.
15. Konuma K (1994). Use and abuse of amphetamines in Japan. In: Cho AK, Segal DS, editors. Amphetamine and its analogs. San Diego: Academic Press. pp. 415-435.
16. Lachman HM, Papolos DF, Saito T, Yu Y-M, Szumlanski CL, Weinshilboum RM (1996). Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphisms and its potential application to neuropsychiatric disorders. Pharmacogenetics 6:243-250.
17. Lett BT (1989). Repeated exposures intensity rather than diminish the rewarding effects of amphetamine, morphine, and cocaine. Psychopharmacology 98:357-362.
18. Maniatis T, Fitsch EF, Sambrook J (1989). Molecular cloning. A laboratory manual 9.16-19. New York: Cold Spring Harbor Laboratory.
19. Mattay VS, Goldberg TE, Fera F, Hariri AR, Tessitore A, Egan MF, et al. (2003). Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 100:6186-6191.
20. Nakamura A, Inada T, Kitao Y, Katayama Y (2001). Association between catechol-O-methyltransferase (COMT) polymorphism and severe alcoholic withdrawal symptoms in male Japanese alcoholics. Addict Biol 6:233-238.
21. Nestler EJ (2000). Genes and addiction. Nat Genet 26:277-281.
22. Nishikawa T, Mataga N, Takashima M, Toru M (1983). Behavioral sensitization and relative hyperresponsiveness of striatal and limbic dopaminergic neurons after repeated methamphetamine treatment. Eur J Pharmacol 88:195-203.
23. Ohmori O, Shinkai T, Kojima H, Terao T, Suzuki T, Mita T, et al. (1998). Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenia. Neurosci Lett 243:109-112.
24. Piazza PV, Deminiere JM, Le Moal M, Shimon H (1989). Factors that predict individual vulnerability to amphetamine self-administration. Science 245:1511-1513.
25. Robinson TE, Becker JB (1986). Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Res Rev 396:157-198.
26. Rotondo A, Mazzanti C, Dell'Osso L, Rucci P, Sullivan P, Bouanani S, et al. (2002). Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 159:23-29.
27. Rujescu D, Giegling I, Gietl A, Hartmann AM, Moller HJ (2003). A functional single nucleotide polymorphism (V158M) in the COMT gene is associated with aggressive personality traits. Biol Psychiatry 54:34-39.
28. Sato M, Chen CC, Akiyama K, Otsuki S (1983). Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 18:429-440.
29. Sato M, Numach Y, Hamamura T (1992). Relapse of paranoid psychotic state in methamphetamine model of schizophrenia. Schizophr Bull 18:115-122.
30. Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, et al. (2001). Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET. Am J Psychiatry 158:1206-1214.
31. Sekine Y, Minabe Y, Ouch Y, Takei N, Iyo N, Nakamura K, et al. (2003). Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry 160:1699-1701.
32. Toda S, McGinty JF, Kalivas PW (2002). Repeated cocaine administration alters the expression of genes in corticolimbic circuitry after a 3-week withdrawal: a DNA macroarray study. J Neurochem 82:1290-1299.
33. Ujike H, Onoue T, Akiyama K, Hamamura T, Otsuki S (1989). Effects of selective D-1 and D-2 dopamine antagonists on development of methamphetamine-induced behavioral sensitization. Psychopharmacology (Berlin) 98:89-92.
34. Vandenbergh DJ, Rodriguez LA, Miller IT, Uhl GR, Lachman HM (1997). Highactivity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. Am J Med Genet 74:439-442.
35. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. (2001). Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377-382.
36. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. (1996). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2:699-703.
37. Yui K, Goto K, Ikemoto S, Ishiguro T, Kamada Y (1999a). Increased sensitivity to stress and episode recurrence in spontaneous recurrence of methamphetamine psychosis. Psychopharmacology (Berlin) 145:267-272.
38. Yui K, Ishiguro T, Goto K, Ikemoto S, Kamata Y (1999b). Spontaneous recurrence of methamphetamine psychosis: increased sensitivity to stress associated with noradrenergic hyperactivity and dopaminergic change. Eur Arch Psychiatry Clin Neurosci 249:103-111.
39. Yui K, Ikemoto S, Goto K, Nishijima K, Yoshino T, Ishiguro T (2002). Spontaneous recurrence of methamphetamine-induced paranoid-hallucinatory states in female subjects: susceptibility to psychotic states and implications for relapse of schizophrenia. Pharmacopsychiatry 35:62-71.